1514 related articles for article (PubMed ID: 18582458)
1. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Toba H; Mitani T; Takahashi T; Imai N; Serizawa R; Wang J; Kobara M; Nakata T
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1064-70. PubMed ID: 20678154
[TBL] [Abstract][Full Text] [Related]
3. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
4. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
6. Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression.
Cavallari LH; Fashingbauer LA; Camp JR; King ST; Geenen DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):146-53. PubMed ID: 18957385
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Yuan J; Jia R; Bao Y
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):118-26. PubMed ID: 17907099
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
10. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
11. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
12. Suppression of transforming growth factor-beta1 gene expression by Danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin-induced diabetic rats.
Zhang YW; Xie D; Xia B; Zhen RT; Liu IM; Cheng JT
Horm Metab Res; 2006 Feb; 38(2):82-8. PubMed ID: 16523407
[TBL] [Abstract][Full Text] [Related]
13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
14. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.
Lian M; Hewitson TD; Wigg B; Samuel CS; Chow F; Becker GJ
Nephrol Dial Transplant; 2012 Mar; 27(3):906-12. PubMed ID: 21908416
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats.
Fujisawa G; Muto S; Okada K; Kusano E; Ishibashi S
Transl Res; 2006 Sep; 148(3):149-56. PubMed ID: 16938653
[TBL] [Abstract][Full Text] [Related]
16. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Kidney Int; 2004 Oct; 66(4):1493-502. PubMed ID: 15458443
[TBL] [Abstract][Full Text] [Related]
18. Anabolic steroid associated to physical training induces deleterious cardiac effects.
Do Carmo EC; Fernandes T; Koike D; Da Silva ND; Mattos KC; Rosa KT; Barretti D; Melo SF; Wichi RB; Irigoyen MC; de Oliveira EM
Med Sci Sports Exerc; 2011 Oct; 43(10):1836-48. PubMed ID: 21407130
[TBL] [Abstract][Full Text] [Related]
19. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
van den Hoven MJ; Waanders F; Rops AL; Kramer AB; van Goor H; Berden JH; Navis G; van der Vlag J
Nephrol Dial Transplant; 2009 Sep; 24(9):2637-45. PubMed ID: 19429930
[TBL] [Abstract][Full Text] [Related]
20. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
